首頁 > 市場調查報告書 > 醫療設備

止血產品市場規模、佔有率及成長分析（按產品、應用、最終用途及地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1902889

止血產品市場規模、佔有率及成長分析（按產品、應用、最終用途及地區分類）－2026-2033年產業預測

Hemostasis Products Market Size, Share, and Growth Analysis, By Products (Topical Hemostasis, Infusible Hemostasis), By Application (Trauma, Surgery), By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，止血產品市場規模將達到 17.8 億美元，到 2025 年將達到 18.8 億美元，到 2033 年將達到 28.9 億美元，在預測期（2026-2033 年）內，複合年成長率為 5.5%。

止血產品市場正經歷強勁成長，這主要得益於醫療領域意識的提高和技術的進步。這些產品對於控制手術和創傷中的出血以及治療各種出血性疾病至關重要。人口老化以及慢性病和外科手術的激增，推動了對這些解決方案的需求。此外，新興市場醫療基礎設施的改善也進一步促進了市場擴張。持續的研發投入正在推出更有效、更安全的止血產品。然而，監管障礙和高成本等挑戰可能會限制市場成長。儘管存在這些障礙，但隨著醫療標準和技術的不斷發展，止血產品領域仍具備良好的發展前景。

止血產品市場促進因素

止血產品市場受到更環保、更安全的止血產品以及旨在控制出血的創新藥物和器械的持續研發的顯著影響。這些技術進步不僅為外科手術中的出血管理提供了更有效的解決方案，還能改善病患的治療效果。隨著醫療機構擴大採用這些先進產品來提高醫療質量，對止血解決方案的需求持續成長，從而推動了該行業的成長。總而言之，這些產品的持續發展在塑造止血護理的未來方面發揮著至關重要的作用。

止血產品市場的限制因素

止血產品市場面臨的主要挑戰之一是其高成本。價格上漲會降低預算有限的醫療機構和某些地區患者獲得這些產品的機會。這種經濟障礙可能會阻礙先進止血解決方案的廣泛應用，限制其市場佔有率，並可能影響病患照護品質。因此，成本仍然是一個突出的限制因素，影響著醫療機構對這些產品的投資意願以及患者獲得所需治療的能力。

止血產品市場趨勢

止血產品市場正呈現出一股顯著的趨勢，即微創技術優先考慮患者的安全和舒適度。包括醫療服務提供者和患者在內的相關人員越來越重視能夠有效控制出血、同時最大限度地減少組織損傷和縮短恢復時間的解決方案。這種轉變正在推動止血產品的創新，催生出能夠改善手術效果並簡化患者照護的新技術和方法。人們越來越傾向於選擇恢復時間更短、住院時間更短的手術方式，這反映了醫療保健領域以價值為導向的整體趨勢，即強調治療方法的品質和效率。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

CSL Behring（Australia）
Haemonetics Corporation（USA）
Octapharma AG（Switzerland）
Baxter International Inc.（USA）
Johnson & Johnson（USA）
Pfizer Inc.（USA）
Becton, Dickinson and Company（USA）
Medtronic plc（Ireland）
Siemens Healthineers AG（Germany）
Abbott Laboratories（USA）
Roche Holding AG（Switzerland）
Thermo Fisher Scientific Inc.（USA）
Grifols, SA（Spain）
Instrumentation Laboratory（Werfen）（USA）
Stago Group（France）
Sysmex Corporation（Japan）
Siemens Healthineers AG（Germany）
Danaher Corporation（USA）
LivaNova PLC（UK）
CryoLife, Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35A2702

Hemostasis Products Market size was valued at USD 1.78 Billion in 2024 and is poised to grow from USD 1.88 Billion in 2025 to USD 2.89 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The hemostasis products market is experiencing robust growth driven by heightened awareness and technological advancements in the medical field. These products are essential for managing bleeding during surgeries and trauma events, as well as treating various bleeding disorders. The increasing aging population, alongside a surge in chronic illnesses and surgical procedures, fuels demand for these solutions. Additionally, improved healthcare infrastructure in emerging markets further supports market expansion. Continuous research and innovation are introducing more effective and safer hemostasis products. However, challenges such as regulatory hurdles and high costs may limit market growth. Despite these obstacles, the hemostasis products sector is well-positioned for ongoing development as healthcare standards and technologies evolve.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemostasis Products market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemostasis Products Market Segments Analysis

Global Hemostasis Products Market is segmented by Products, Application, End Use and region. Based on Products, the market is segmented into Topical Hemostasis, Infusible Hemostasis and Advanced Hemostasis. Based on Application, the market is segmented into Trauma, Surgery, Hemophilia, Myocardial Infarction, Stroke and Thrombosis. Based on End Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemostasis Products Market

The Hemostasis Products market is significantly influenced by advancements in the development of greener and safer hemostatic products, as well as innovative agents and devices designed to control bleeding. These technological enhancements not only provide more effective solutions for managing bleeding during surgical procedures but also lead to better patient outcomes. As healthcare providers increasingly adopt these advanced products to elevate the quality of care, the demand for hemostasis solutions continues to rise, driving growth within this sector. Overall, the continuous evolution of these products plays a crucial role in shaping the future of hemostasis treatments.

Restraints in the Hemostasis Products Market

A significant challenge facing the hemostasis products market is the high cost of these items. The elevated prices can make them less attainable for healthcare facilities operating with limited budgets, as well as for patients in certain areas. This financial barrier can impede the widespread adoption of advanced hemostasis solutions, thereby restricting their presence in the market and potentially impacting the quality of patient care. As a result, the cost factor remains a prominent limitation, influencing both healthcare providers' willingness to invest in these products and patients' ability to access necessary treatments.

Market Trends of the Hemostasis Products Market

The Hemostasis Products market is witnessing a significant trend towards minimally invasive techniques that prioritize patient safety and comfort. Stakeholders in healthcare, including providers and patients, are increasingly favoring solutions that effectively manage bleeding while minimizing tissue damage and recovery time. This shift is driving innovation in hemostasis products, as new technologies and practices emerge to enhance surgical outcomes and streamline patient care. The rising preference for procedures that allow for quicker recovery and shorter hospital stays reflects the overarching trend in healthcare towards value-based care, emphasizing quality and efficiency in treatment methodologies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Hemostasis Products Market Size by Products & CAGR (2026-2033)

Market Overview
Topical Hemostasis
- Collagen
- Oxidized Regenerated Cellulose
- Gelatin
- Polysaccharide
Infusible Hemostasis
- Platelet Concentrates from Donor Blood
- FVIII Derived from Blood
- Fresh Frozen Plasma
- Prothrombin Complex
Advanced Hemostasis
- Flowable
- Thrombin
- Fibrin
- Synthetic Sealants

Global Hemostasis Products Market Size by Application & CAGR (2026-2033)

Market Overview
Trauma
Surgery
Hemophilia
Myocardial Infarction
Stroke
Thrombosis

Global Hemostasis Products Market Size by End Use & CAGR (2026-2033)

Market Overview
Hospitals
Ambulatory Surgical Centers
Others

Global Hemostasis Products Market Size & CAGR (2026-2033)

North America (Products, Application, End Use)
- US
- Canada
Europe (Products, Application, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Products, Application, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Products, Application, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Products, Application, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haemonetics Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Instrumentation Laboratory (Werfen) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stago Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LivaNova PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CryoLife, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments